ArticleHealth services research2018
Medicare Spending for Breast, Prostate, Lung, and Colorectal Cancer Patients in the Year of Diagnosis and Year of Death.
Article in Health services research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05903885 (Using a Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Using a Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of the Economic Burden of Prostate Cancer: Direct and Indirect Cost Perspectives.PharmacoEconomics · 2026Pooled it
- Outcomes of Medicare-covered diabetes self-management training for cancer survivors with diabetes.Journal of cancer survivorship : research and practice · 2025Article
- Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy.JNCI cancer spectrum · 2024Article
- Cost-effectiveness analysis of MRI, CE-CT and 18F-FDG PET/CT for detecting colorectal liver metastases eligible for hepatic resection.Frontiers in oncology · 2023Article
- Developing a co-production strategy to facilitate the adoption and implementation of evidence-based colorectal cancer screening interventions for rural health systems: a pilot study.Implementation science communications · 2022Article
- Review
- Vitamin D supplementation to the older adult population in Germany has the cost-saving potential of preventing almost 30 000 cancer deaths per year.Molecular oncology · 2021Article
- Colorectal cancer screening in the COVID-19 era.World journal of gastrointestinal oncology · 2021Review
- End-of-Life Cost Trajectories in Cancer Patients Treated by Medicare versus the Veterans Health Administration.Journal of the American Geriatrics Society · 2021Article
- Review
- A Network Pharmacology-Based Study on the Anti-Lung Cancer Effect of Dipsaci Radix.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Spending for Advanced Cancer Diagnoses: Comparing Recurrent Versus De Novo Stage IV Disease.Journal of oncology practice · 2019Article
- The impact of smartphone applications on bowel preparation, compliance with appointments, cost-effectiveness, and patients' quality of life for the colonoscopy process: A scoping review.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo characterize spending patterns for Medicare patients with incident breast, prostate, lung, and colorectal cancer. DATA SOURCES/STUDY SETTING/STUDY
design2007-2012 data from the Surveillance, Epidemiology, and End Results Program linked with Medicare fee-for-service claims. DATA COLLECTION/EXTRACTION
methodsWe calculate per-patient monthly and yearly mean and median expenditures, by cancer type, stage at diagnosis, and spending category, over the years of diagnosis and death. PRINCIPAL
findingsOver the year of diagnosis, mean spending was $35,849, $26,295, $55,597, and $63,063 for breast, prostate, lung, and colorectal cancer, respectively. Over the year of death, spending was similar across different cancer types and stage at diagnosis.
conclusionsCharacterization of Medicare spending according to clinically meaningful categories may assist development of oncology alternative payment models and cost-effectiveness models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.